Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.
about
Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus.Real-life effectiveness and tolerability of vildagliptin and other oral glucose-lowering therapies in patients with type 2 diabetes in Germany.Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylureaEffectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE studyEfficacy and safety of a single-pill combination of vildagliptin and metformin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trialTreatment Compliance with Fixed-Dose Combination of Vildagliptin/Metformin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy: A 24-Week Observational Study.Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitusEfficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agentEfficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study.Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision studyEffect of Vildagliptin Versus Sulfonylurea in Muslim Patients with Type 2 Diabetes Fasting During Ramadan in Egypt: Results from VIRTUE StudyLinagliptin as add-on therapy to insulin for patients with type 2 diabetesVildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin.A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus.A review of gliptins in 2011.Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.Clinical pharmacokinetics and pharmacodynamics of vildagliptin.Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes.Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patientsEffectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study.Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: an observational study.Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus.Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.Effects of vildagliptin/metformin therapy on patient-reported outcomes: work productivity, patient satisfaction, and resource utilization.Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION)Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage.
P2860
Q33785117-55E02C13-1462-45FF-B633-ABB70F4EDDD8Q33785162-F9845AB2-37E6-4F53-9F39-834DA8383573Q34543050-2F9F0BBF-BA40-422E-8824-A93A1352B29AQ35142675-C538351A-18FF-41E1-AB61-408D96805676Q35217929-AD603052-B0A8-4706-B7E0-999F351B09B2Q35674552-177C3AAC-3ABB-4C37-885C-FD3495213018Q35997324-6F9E8854-A922-4A6C-8A24-18F77A5FA9CDQ36192977-4B1DFF5F-9C48-46EA-946C-7C558E60F2BFQ36365793-4E9C4410-C6A1-4525-814E-8E3B8B322010Q37153711-56FB6AB4-3787-4F54-899F-EFB2675CF384Q37239317-22463EB9-7C71-4AD9-AC94-BE1E92A6F66BQ37281205-EC8755AF-12D1-49C9-9A07-BE859FAC5845Q37471910-F99C6109-17A2-41B1-A158-216C1581E317Q37652091-4A70514A-3298-4706-BF2D-F6E99F2FE897Q37965612-5A801D28-1136-4F29-8D71-46E1B81081DAQ37982112-8EB99E1F-8886-46ED-8E01-10307DF6ED2EQ37984567-73819D53-95A8-4D44-AC19-FB623469DB91Q37991385-88568822-10C7-4D60-BE1C-BEE721E044BEQ38189114-9AAE3FC1-CBA0-4F88-A8FB-402429D8569AQ38212472-CC98ED5A-B56B-4863-A17D-E7C25C55E123Q38452890-99A0A9E7-0ABD-43BE-9B7C-6D67853A0001Q39454846-774CB2AF-8CBA-4795-BD1D-1D4B339CD3A6Q44616554-0C1CBFF9-0F0E-4CC3-9414-B2A9DF05BEEEQ44814545-68266E91-AE89-4F17-868F-30CF7A294012Q45011062-EBF8C306-9926-4760-82AE-EF034BA804E8Q51206578-BF2C00F8-510B-4BD8-AE97-D04D25EFAA0AQ51281907-1C869293-E2B5-4ABB-A355-F258FC0E46BAQ51360460-98E990AB-34ED-40FB-8D2C-F0B36496441AQ51363561-E0F98C3F-7B21-4D6B-9CDE-AC877A8FB7D8
P2860
Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical evidence and mechanis ...... ction when added to metformin.
@en
Clinical evidence and mechanis ...... ction when added to metformin.
@nl
type
label
Clinical evidence and mechanis ...... ction when added to metformin.
@en
Clinical evidence and mechanis ...... ction when added to metformin.
@nl
prefLabel
Clinical evidence and mechanis ...... ction when added to metformin.
@en
Clinical evidence and mechanis ...... ction when added to metformin.
@nl
P2860
P1476
Clinical evidence and mechanis ...... ction when added to metformin.
@en
P2093
P2860
P304
P356
10.1111/J.1463-1326.2010.01321.X
P50
P577
2011-03-01T00:00:00Z